(Q40932548)

English

Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study

scientific article published on 2 June 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Dean J Kereiakes

3

object named as

Dean J Kereiakes

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

author name string

Henry Punzi

1

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Joel M Neutel

2

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Ali Shojaee

4

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

William F Waverczak

5

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Robert Dubiel

6

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Jen-Fue Maa

7

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

publication date

2 June 2010

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Therapeutic advances in cardiovascular disease

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

209-221

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Fixed-dose combinations improve medication compliance: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

The role of existing and newer calcium channel blockers in the treatment of hypertension

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

2009 Canadian Hypertension Education Program recommendations: the scientific summary--an annual update

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

Role of ambulatory blood pressure monitoring in the management of hypertension

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

What factors contribute to the inadequate control of elevated blood pressure?

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

Blood pressure surge on rising

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

Hypertension in adults across the age spectrum: current outcomes and control in the community

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

2007 Guidelines for the Management of Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

Circadian variation and triggers of onset of acute cardiovascular disease

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Associati

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

ASH Position Paper: Home and ambulatory blood pressure monitoring. When and how to use self (home) and ambulatory blood pressure monitoring.

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

Evaluation of population pharmacokinetics and exposure-response relationship with coadministration of amlodipine besylate and olmesartan medoxomil

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

Cardiovascular protection and blood pressure reduction: a meta-analysis

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

Telmisartan to prevent recurrent stroke and cardiovascular events

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F1753944710374745

21 January 2018

Identifiers

10.1177/1753944710374745

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40932548&oldid=1910868742"